{"created":"2023-05-15T14:48:49.035063+00:00","id":66870,"links":{},"metadata":{"_buckets":{"deposit":"2c9dbb35-68b5-4fd3-a99a-b9a33540fb0e"},"_deposit":{"created_by":1,"id":"66870","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"66870"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00066870","sets":["10:29"]},"author_link":["657481","657480","657477","657483","657479","657487","657476","657472","657471","657475","657488","657470","657485","657484","657482","657474","657478","657486","657473"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2017-05-26","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent clinically used for various cancers. However, repeated use of this agent leads to tumor-decreased vascularity and hypoxia, which results in drug delivery deficiency and induction of malignant behaviors in tumors. To address this, we focused on a theranostic agent, 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), which possesses high tissue permeability and can target the over-reduced state under hypoxia within tumors. The efficacy of internal radiotherapy with 64Cu-ATSM was examined in mice bearing tumors with bevacizumab-induced vascular decrease and hypoxia. Methods: Human colon carcinoma HT-29 tumor-bearing mice were treated with bevacizumab (5 mg/kg twice a week) for 3 weeks to produce a model for tumors with bevacizumab-induced vascular decrease and hypoxia. Characteristics within the bevacizumab-treated tumors were examined. Dual-isotope simultaneous SPECT/PET/CT imaging with a blood pool-detecting agent 99mTc-labeled human serum albumin and 64Cu-ATSM was performed. In vivo treatment study was then performed. Results: The bevacizumab-treated HT-29 tumors showed decreased blood vessel density, activation of the HIF-1 signaling pathway and upregulation of genes involved in this pathway, and increased uptake of 64Cu-ATSM, compared to the control. SPECT/PET/CT imaging showed reduced vascularity and increased proportion of hypoxic areas in the bevacizumab-treated tumors. 64Cu-ATSM therapy was effective to inhibit tumor growth and prolong survival in the bevacizumab-treated tumor-bearing mice without major adverse effects. Conclusion: 64Cu-ATSM therapy effectively enhanced anti-tumor effects in tumors with bevacizumab-induced vascular decrease and hypoxia. 64Cu-ATSM therapy could be an additional treatment to antiangiogenic therapy. ","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第12回日本分子イメージング学会学術集会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yoshii, Yukie"}],"nameIdentifiers":[{"nameIdentifier":"657470","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimoto, Mitsuyoshi"}],"nameIdentifiers":[{"nameIdentifier":"657471","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsumoto, Hiroki"}],"nameIdentifiers":[{"nameIdentifier":"657472","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Takako"}],"nameIdentifiers":[{"nameIdentifier":"657473","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong"}],"nameIdentifiers":[{"nameIdentifier":"657474","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Inubushi, Masayuki"}],"nameIdentifiers":[{"nameIdentifier":"657475","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"657476","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fujibayashi, Yasuhisa"}],"nameIdentifiers":[{"nameIdentifier":"657477","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"657478","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"657479","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉井 幸恵","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657480","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉本 光喜","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657481","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"古川 高子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657482","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"張 明栄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657483","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"犬伏 正幸","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657484","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 厚至","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657485","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"藤林 康久","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657486","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東 達也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657487","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"657488","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia: Imaging analysis with dual-isotope simultaneous SPECT/PET/CT","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia: Imaging analysis with dual-isotope simultaneous SPECT/PET/CT"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-08-02"},"publish_date":"2018-08-02","publish_status":"0","recid":"66870","relation_version_is_last":true,"title":["64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia: Imaging analysis with dual-isotope simultaneous SPECT/PET/CT"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:43:59.650303+00:00"}